Wednesday, November 16, 2016
Print Current Session:
|
|
Wednesday
SESSION 31:
MONITORING HEPARIN; SCREENING FOR AND ASSESSING ATHEROSCLEROTIC RISK; ANTI- ATHEROSCLEROSIS TREATMENT CHANGES IN LIGHT OF NEW TRIAL FINDINGS; UPDATE ON TIMING OF SURGERY IN PATIENTS WITH CORONARY STENTS
Moderators:Gary M. Ansel, MD / Russell H. Samson, MD, RVT, FACS
|
|
SESSION 31 SCHEDULE | |
6:40 AM - 6:45 AM | Incidence And Importance Of Heparin Resistance In Vascular Procedures And How Measurement Of ACT Can Offset This Problem: Value Of Medtronic Hemostasis Management System |
Presenter(s):Arno M. Wiersema, MD, PhD / Kak Khee Yeung, MD, PhD / Jan D. Blankensteijn, MD | |
View Slides in PDF | |
6:46 AM - 6:51 AM | Pleiotropic Effect Of Statins: What Are They And How Should They Be Monitored |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
View Slides in PDF | |
6:52 AM - 6:57 AM | The Value Of Ultrasound Screening Of Femoral And Carotid Arteries To Predict Atherosclerotic Risk And What To Do About It |
Presenter(s):Andrew N. Nicolaides, MS, FRCS | |
View Slides in PDF | |
6:58 AM - 7:03 AM | The VIVA RCT Is A Game Changer: It Shows That Population Based Screening For AAA, PAD And Hypertension Allows Intensive Medical Treatment With Statins And Anti-Hypertensives And That These Drugs Save Lives (7%) |
Presenter(s):Jes S. Lindholt, MD | |
View Slides in PDF | |
7:04 AM - 7:09 AM | Current Role Of PCSK 9 Inhibitors In LDL-Cholesterol (LDL-C) Management: How Do They Work And When Should They Be Given (Alirocumab-Praluent From Sanofi & Regeneron And Evolocumab-Repatha From Amgen) |
Presenter(s):Ron Waksman, MD | |
View Slides in PDF | |
7:10 AM - 7:15 AM | How To Manage Muscle Pain And Apparent Statin Intolerance In Patients On Statins: It Can Be Often Done Safely And Effectively Without Stopping Statins: What Does The GAUSS-3 Trial Tell Us About Controlling The Side Effects Of Statins |
Presenter(s):Don Poldermans, MD | |
View Slides in PDF | |
7:16 AM - 7:21 AM | Why LDL-C (Or Non-HDL-C) Levels Are Important Guides To Treatment And Should Be Followed In Primary And Secondary Event Prevention For Vascular Patients At Risk: Coronary Lesions Regress When LDL-C Is <80 mm/dL |
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Caron B. Rockman, MD | |
View Slides in PDF | |
7:22 AM - 7:27 AM | Value Of Ezetimibe (Zetia) In Decreasing Death, Stroke And MI Rates When Added To Simvastatin: What Value Of LDL-C Should Our Patients Strive To Achieve: The IMPROVE-IT Trial: What Does The HOPE 3 Trial Tell Us About Crestor And Primary Prevention |
Presenter(s):Ido Weinberg, MD, MSc | |
View Slides in PDF | |
7:28 AM - 7:33 AM | New Key Findings From The JUPITER Trial: Statins (Crestor) Have Variability In Their LDL-C Lowering Ability; The Degree Of Cardiovascular Risk Reduction Correlates With The Percent LDL-C Reduction: Therapeutic Implications |
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC / Jonathan Newman, MD | |
View Slides in PDF | |
7:34 AM - 7:39 AM | What Is New About Optimal Timing For Elective Vascular Surgery After Coronary Stenting For Angina; For MIs; With BMSs; With DESs: Things Have Changed: Risks Are Higher If The Stenting Was Done For An MI |
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC | |
View Slides in PDF | |
7:40 AM - 7:46 AM | Panel Discussion |
END OF SESSION 31 | |
previous | next |